OncoMed Pharmaceuticals, Inc. Appoints Michael Wyzga to Board of Directors
Published: Oct 17, 2013
REDWOOD CITY, Calif., Oct. 17, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the appointment of independent director Michael Wyzga to the company's Board of Directors. Mr. Wyzga will chair OncoMed's Audit Committee.
Help employers find you! Check out all the jobs and post your resume.